PUBLISHED DATE : Aug 2022 | Pages : 317
Fill out your details & get your free sample
Clinical Trials Outsourcing Market Size, Share, Growth Forecast by:
Industry Analysis Report, Regional Outlook, Price Trends & Forecast, 2022-2027
317 Pages
117 Tables
172 Charts
5 Regions
18 Countries
25 Companies
4 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2027) | USD 56.30 Billion |
| Market Size (2022) | USD 38.14 Billion |
| CAGR (2022-2027) | 6.71% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Clinical Trial Phase (Phase I, Phase II, Phase III, Phase IV), End-Users (Small & Mid-Size Companies, Large Size Companies), Application (Cancer, CVDs, Infectious Diseases, Infectious Diseases, Musculoskeletal Diseases, Nervous System Disorders, Other Diseases) |
| Geographic Analysis | North America, Europe, APAC, Latin America, and MEA |
| Countries Covered | US, Canada, UK, Germany, France, Spain, China, Australia, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, and UAE |
The global clinical trials outsourcing market is expected to grow at a CAGR of 6.71% from 2022 to 2027 and is expected to reach $56.30 billion by 2027 from $38.14 billion in 2021. The pharma & biotech companies hire other companies to conduct the clinical trials, as the companies do not have the expertise, time, or infrastructure to do the same. Outsourcing clinical trials delivers advantages such as cost efficiency, minimum timeline, and best result delivery. Most clinical trials are outsourced to contract research organizations and third-party vendors. It has helped to indicate what works for humans and what doesn't by testing them on humans in a professional setup. Such factors contribute to the demand in the global clinical trials outsourcing market.
Outsourcing clinical trials delivers significant advantages in terms of cost as well. Clinical drug development trials are vital, requiring higher expenditure and high-class infrastructure and expertise. Clinical trial processes are complex, so sponsors continuously face pressure from regulatory authorities, insurers, and medical communities to reduce costs by improving development size, pipeline expansion, drug quality, and safety and to meet regulatory expectations.
Most Biopharmaceutical companies spend their higher expenditure on research & development activities and clinical trials, and in the end, lower chances of success rate impact the company’s growth largely. Outsourcing clinical trials efficiently reduces this complexity. Remote trials can reduce around 25 to 30% trials cost due to the services associated with patient travel and the number of staff required to monitor the site, boosting the global Outsourcing clinical trials market.
Across the world, the rising patient population is one of the major problems for developed countries, as their healthcare expenditure is increasing. Hence, there is a demand for advanced treatments which provide value-based solutions to the patients. Biopharmaceutical companies constantly look for new drugs and derived clinical trial activities. Research and development activities are significant in the pharmaceutical and biopharmaceutical industry, giving high potential for the clinical trial outsourcing market and related activities.
Impact of COVID-19 Pandemic
The COVID-19 gave an absolute massive shift and forced the clinical trial industries to look for outsourcing. Clinical trial complexity is a significant factor that drives clinical trial outsourcing. Robust pipelines and stringent regulations in clinical trials operate the clinical development services.
Virtual Clinical Trials Market: Future of Clinical Trial Outsourcing Market
Virtual clinical trials is a rapidly increasing trend in biopharma industries. It is one of the new clinical trial models, a highly underutilized method for conducting clinical trials and clinical research. Virtual clinical trials are cost-effective, time-saving, and easier for participants. Virtual collaboration strategies in clinical trials, using clinical trials software, allow businesses to work rapidly and more efficiently, eliminates the need for document sharing to additional office locations, and reduce the burden helping the clinical trial outsourcing market grow.
INSIGHTS BY PHASE
By phase, the global clinical trials outsourcing market segments: Phase I, Phase II, Phase III & Phase IV. Phase III accounts for the largest global clinical trial outsourcing market share. Lower chances of new drugs passing from phase II to phase III, clinical trials outsourcing services prominently focus on a well-established analysis of phase II clinical trials. In phase III, outsourcing services check the side effects, the efficacy rate of drugs, and how specifically new drugs work compared to existing standard drugs.
INSIGHTS BY APPLICATION
Cancer is one of the leading and highly impacting worldwide diseases responsible for deaths. Due to the increasing prevalence of cancer conditions, demand increase for medications. In 2021, the cancer segment accounted for 33.64% market share in the global clinical trial outsourcing market. By application, the clinical trial outsourcing market is segmented into cancer, cardiovascular disease, nervous system disease, infectious disease, gastroenterology diseases, Musculoskeletal disease, nervous system, and other disease applications.
INSIGHTS BY END-USERS
The clinical trials outsourcing market by end-users is segmented into two types of companies Small & Mid-Size Companies and large size companies. In which small & mid-size companies segment accounted for higher market share and dominated the other segments. Large companies have annual revenue of over USD 10 billion, and small companies have less than USD 1 billion in revenue.
Due to high research and development activities for new drugs by pharmaceutical and biotech companies, the later stages of the clinical trials are usually outsourced, and only the initial discovery phase is performed in-house. The increasing number of small and mid-size biopharmaceutical companies and the presence of big biotech and pharma companies’ demanding clinical trial activities are consistently increasing globally, boosting the global clinical trial outsourcing market.
The global clinical trial outsourcing market is highly competitive. Many international, national, regional, and local market players make it competitive by delivering high advances and outsourcing services. Increasing competition in the pharma industry directly impacts clinical trial outsourcing market competitiveness. Also, the lower success rate of clinical trials, outsourcing services highly focused on the successful delivery and best result of clinical trials and try to be achieved high market size in the international market.
In the global clinical trial outsourcing market, some key players such as IQVIA, Labcorp, Charles River Laboratory, Wuxi AppTec, Syneos Health, PPD (Thermo Fisher Scientific), and Icon Plc are contributing to the high market size by delivering high-quality outsourcing services for biopharma companies, government, and academic institutes. The key strategy adoptions such as partnership, collaboration with key players, and other prominent players make high competition in the market. These key strategies of major market players and increased the clinical research studies by them derived high market share in the market.
Frequently Asked Questions
What is the expected growth of the clinical trials outsourcing market in the global market?
The clinical trials outsourcing market was valued at USD 38.14 billion in 2021 and is expected to reach USD 56.30 billion industry by 2027 with a CAGR of 6.71%.
Who are the major players in the clinical trials outsourcing market?
Major clinical trial outsourcing market players are Charles River Laboratories, IQVIA, ICON plc, Labcorp Drug Development, Syneos Health, Thermo Fischer Scientific, Wuxi AppTec, and Paraxel.
What is the Growth Rate of the clinical trials outsourcing market?
The clinical trials outsourcing market will grow by 6.71% from 2021-2027.
How does COVID-19 impact the market growth of clinical trials outsourcing market share?
The COVID-19 pandemic has given an absolute massive shift and has forced the clinical trial industries to look for outsourcing.
What are the factors driving the clinical trials outsourcing market growth?
The rising need for drug discovery and increasing expenditure, increasing demand for large-molecule development, rare disease & personalized medicines are some factors driving the market growth.
The clinical trials outsourcing market by revenue is expected to grow at a CAGR of close to 6.71% during the period 2022–2027.
The following factors are likely to contribute to the growth of the clinical trials outsourcing market during the forecast period:
Base Year: 2021
Forecast Year: 2022-2027
The report considers the present scenario of the clinical trials outsourcing market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.
Key Vendors:
Other Prominent Vendors
Segmentation by Application
Segmentation by Clinical Trial Phase
Segmentation by End-Users
Segmentation by Geography
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY CLINICAL TRIAL PHASE
4.3.2 MARKET SEGMENTATION BY APPLICATION
4.3.3 MARKET SEGMENTATION BY END USER
4.3.4 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
8 PREMIUM INSIGHTS
8.1 OVERVIEW
8.1.1 TRENDS IN CLINICAL TRIALS OUTSOURCING
9 MARKET OPPORTUNITIES & TRENDS
9.1 RISING DEMAND FOR PATIENT-CENTRIC & DECENTRALIZED CLINICAL TRIALS
9.2 REVOLUTIONIZING EFFECTS OF AI ON CLINICAL TRIALS
9.3 ENTRY OF START-UPS SPECIALIZING IN DRUG DISCOVERY
9.4 INCREASING ADOPTION OF SYNTHETIC CLINICAL TRIALS
10 MARKET GROWTH ENABLERS
10.1 SURGE IN DRUG DISCOVERY INITIATIVES AND ASSOCIATED EXPENDITURE
10.2 HIGH DEMAND FOR LARGE MOLECULE PRODUCTS & PERSONALIZED MEDICINES
10.3 INITIATIVES TO IMPROVE EFFICIENCY IN CLINICAL TRIALS
10.4 RISE IN STRATEGIC PARTNERSHIPS AND R&D COLLABORATIONS
11 MARKET RESTRAINTS
11.1 GEOGRAPHICAL LOCATIONS AND CRUCIAL REGULATORY ASPECTS FOR CLINICAL TRIALS
11.2 LONG TIMELINES AND LACK OF TRANSPARENCY & SPECIFICITY
11.3 INCREASING COMPLEXITY OF CLINICAL TRIALS
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.1.1 INSIGHTS BY GEOGRAPHY
12.1.2 INSIGHTS BY CLINICAL TRIALS PHASE
12.1.3 INSIGHTS BY APPLICATION
12.1.4 INSIGHTS BY END USERS
12.2 MARKET SIZE & FORECAST
12.3 FIVE FORCES ANALYSIS
12.3.1 THREAT OF NEW ENTRANTS
12.3.2 BARGAINING POWER OF SUPPLIERS
12.3.3 BARGAINING POWER OF BUYERS
12.3.4 THREAT OF SUBSTITUTES
12.3.5 COMPETITIVE RIVALRY
13 PHASE
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.1.1 MARKET SIZE & FORECAST
13.2 MARKET OVERVIEW
13.3 PHASE III
13.3.1 MARKET OVERVIEW
13.3.2 MARKET BY GEOGRAPHY
13.4 PHASE II
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 MARKET BY GEOGRAPHY
13.5 PHASE IV
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.5.3 MARKET BY GEOGRAPHY
13.6 PHASE I
13.6.1 MARKET OVERVIEW
13.6.2 MARKET SIZE & FORECAST
13.6.3 MARKET BY GEOGRAPHY
14 APPLICATION
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 CANCER
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 MARKET BY GEOGRAPHY
14.4 CARDIOVASCULAR DISEASES
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 MARKET BY GEOGRAPHY
14.5 NERVOUS SYSTEM DISORDERS
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.5.3 MARKET BY GEOGRAPHY
14.6 INFECTIOUS DISEASES
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.6.3 MARKET BY GEOGRAPHY
14.7 MUSCULOSKELETAL DISEASES
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
14.7.3 MARKET BY GEOGRAPHY
14.8 GASTROENTEROLOGY DISEASES
14.8.1 MARKET OVERVIEW
14.8.2 MARKET SIZE & FORECAST
14.8.3 MARKET BY GEOGRAPHY
14.9 OTHERS
14.9.1 MARKET OVERVIEW
14.9.2 MARKET SIZE & FORECAST
14.9.3 MARKET BY GEOGRAPHY
15 END USER
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 SMALL & MID-SIZE COMPANIES
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 MARKET BY GEOGRAPHY
15.4 LARGE ENTERPRISES
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 MARKET BY GEOGRAPHY
16 GEOGRAPHY
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 GEOGRAPHIC OVERVIEW
17 NORTH AMERICA
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.3 PHASE
17.3.1 MARKET SIZE & FORECAST
17.4 APPLICATION
17.4.1 MARKET SIZE & FORECAST
17.5 END USER
17.5.1 MARKET SIZE & FORECAST
17.6 KEY COUNTRIES
17.6.1 US: MARKET SIZE & FORECAST
17.6.2 CANADA: MARKET SIZE & FORECAST
18 EUROPE
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.3 PHASE
18.3.1 MARKET SIZE & FORECAST
18.4 APPLICATION
18.4.1 MARKET SIZE & FORECAST
18.5 END USER
18.5.1 MARKET SIZE & FORECAST
18.6 KEY COUNTRIES
18.6.1 GERMANY: MARKET SIZE & FORECAST
18.6.2 UK: MARKET SIZE & FORECAST
18.6.3 FRANCE: MARKET SIZE & FORECAST
18.6.4 SPAIN: MARKET SIZE & FORECAST
18.6.5 ITALY: MARKET SIZE & FORECAST
19 APAC
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.3 PHASE
19.3.1 MARKET SIZE & FORECAST
19.4 APPLICATION
19.4.1 MARKET SIZE & FORECAST
19.5 END USER
19.5.1 MARKET SIZE & FORECAST
19.6 KEY COUNTRIES
19.6.1 CHINA: MARKET SIZE & FORECAST
19.6.2 JAPAN: MARKET SIZE & FORECAST
19.6.3 INDIA: MARKET SIZE & FORECAST
19.6.4 AUSTRALIA: MARKET SIZE & FORECAST
19.6.5 SOUTH KOREA: MARKET SIZE & FORECAST
20 LATIN AMERICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.3 PHASE
20.3.1 MARKET SIZE & FORECAST
20.4 APPLICATION
20.4.1 MARKET SIZE & FORECAST
20.5 END USER
20.5.1 MARKET SIZE & FORECAST
20.6 KEY COUNTRIES
20.6.1 BRAZIL: MARKET SIZE & FORECAST
20.6.2 MEXICO: MARKET SIZE & FORECAST
21 MIDDLE EAST & AFRICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.3 PHASE
21.3.1 MARKET SIZE & FORECAST
21.4 APPLICATION
21.4.1 MARKET SIZE & FORECAST
21.5 END USER
21.5.1 MARKET SIZE & FORECAST
21.6 KEY COUNTRIES
21.6.1 TURKEY: MARKET SIZE & FORECAST
21.6.2 EGYPT: MARKET SIZE & FORECAST
21.6.3 SOUTH AFRICA: MARKET SIZE & FORECAST
21.6.4 SAUDI ARABIA: MARKET SIZE & FORECAST
22 COMPETITIVE LANDSCAPE
22.1 COMPETITION OVERVIEW
22.2 MARKET SHARE ANALYSIS
22.2.1 CHARLES RIVER LABORATORIES
22.2.2 IQVIA
22.2.3 ICON PLC
22.2.4 LABCORP DRUG DEVELOPMENT
22.2.5 SYNEOS HEALTH
22.2.6 THERMO FISCHER SCIENTIFIC
22.2.7 WUXI APPTEC
22.2.8 PARAXEL
23 KEY COMPANY PROFILES
23.1 CHARLES RIVER LABORATORIES
23.1.1 BUSINESS OVERVIEW
23.1.2 PRODUCT OFFERINGS
23.1.3 KEY STRATEGIES
23.1.4 KEY STRENGTHS
23.1.5 KEY OPPORTUNITIES
23.2 IQVIA
23.2.1 BUSINESS OVERVIEW
23.2.2 PRODUCT OFFERINGS
23.2.3 KEY STRATEGIES
23.2.4 KEY STRENGTHS
23.2.5 KEY OPPORTUNITIES
23.3 ICON PLC
23.3.1 BUSINESS OVERVIEW
23.3.2 PRODUCT OFFERINGS
23.3.3 KEY STRATEGIES
23.3.4 KEY STRENGTHS
23.3.5 KEY OPPORTUNITIES
23.4 LABCORP DRUG DEVELOPMENT
23.4.1 BUSINESS OVERVIEW
23.4.2 SERVICE OFFERINGS
23.4.3 KEY STRATEGIES
23.4.4 KEY STRENGTHS
23.4.5 KEY OPPORTUNITIES
23.5 SYNEOS HEALTH
23.5.1 BUSINESS OVERVIEW
23.5.2 SERVICE OFFERINGS
23.5.3 KEY STRATEGIES
23.5.4 KEY STRENGTHS
23.5.5 KEY OPPORTUNITIES
23.6 THERMO FISHER SCIENTIFIC
23.6.1 BUSINESS OVERVIEW
23.6.2 SERVICE OFFERINGS
23.6.3 KEY STRATEGIES
23.6.4 KEY STRENGTHS
23.6.5 KEY OPPORTUNITIES
23.7 WUXI APPTEC
23.7.1 BUSINESS OVERVIEW
23.7.2 SERVICE OFFERINGS
23.7.3 KEY STRATEGIES
23.7.4 KEY STRENGTHS
23.7.5 KEY OPPORTUNITIES
23.8 PARAXEL
23.8.1 BUSINESS OVERVIEW
23.8.2 SERVICE OFFERINGS
23.8.3 KEY STRATEGIES
23.8.4 KEY STRENGTHS
23.8.5 KEY OPPORTUNITIES
24 OTHER PROMINENT VENDORS
24.1 ADVANCED CLINICAL
24.1.1 BUSINESS OVERVIEW
24.1.2 SERVICE OFFERINGS
24.2 BIOANALYTIX
24.2.1 BUSINESS OVERVIEW
24.2.2 SERVICE OFFERINGS
24.3 CURIA GLOBAL
24.3.1 BUSINESS OVERVIEW
24.3.2 SERVICE OFFERINGS
24.4 CMED
24.4.1 BUSINESS OVERVIEW
24.4.2 SERVICE OFFERINGS
24.5 CROMOS PHARMA
24.5.1 BUSINESS OVERVIEW
24.5.2 SERVICE OFFERINGS
24.6 CRITERIUM
24.6.1 BUSINESS OVERVIEW
24.6.2 SERVICE OFFERINGS
24.7 KCR S.A.
24.7.1 BUSINESS OVERVIEW
24.7.2 SERVICE OFFERINGS
24.8 MEDPACE
24.8.1 BUSINESS OVERVIEW
24.8.2 SERVICE OFFERINGS
24.9 MEDELIS
24.9.1 BUSINESS OVERVIEW
24.9.2 SERVICE OFFERINGS
24.10 OCT GROUP
24.10.1 BUSINESS OVERVIEW
24.10.2 SERVICE OFFERINGS
24.11 PROTRIALS RESEARCH
24.11.1 BUSINESS OVERVIEW
24.11.2 SERVICE OFFERINGS
24.12 PROMETRIKA
24.12.1 BUSINESS OVERVIEW
24.12.2 SERVICE OFFERINGS
24.13 QUALITY DATA SERVICES
24.13.1 BUSINESS OVERVIEW
24.13.2 SERVICE OFFERINGS
24.14 QPS
24.14.1 BUSINESS OVERVIEW
24.14.2 SERVICE OFFERINGS
24.15 SOFPROMED
24.15.1 BUSINESS OVERVIEW
24.15.2 SERVICE OFFERINGS
24.16 VERISTAT
24.16.1 BUSINESS OVERVIEW
24.16.2 SERVICE OFFERINGS
24.17 WORLDWIDE CLINICAL TRIALS
24.17.1 BUSINESS OVERVIEW
24.17.2 SERVICE OFFERINGS
25 REPORT SUMMARY
25.1 KEY TAKEAWAYS
25.2 STRATEGIC RECOMMENDATIONS
26 QUANTITATIVE SUMMARY
26.1 MARKET BY GEOGRAPHY
26.2 MARKET BY PHASE
26.3 MARKET BY APPLICATION
26.4 MARKET BY END USER
26.5 MARKET BY PHASE
26.5.1 PHASE III: GEOGRAPHY DISTRIBUTION
26.5.2 PHASE II: GEOGRAPHY DISTRIBUTION
26.5.3 PHASE IV: GEOGRAPHY DISTRIBUTION
26.5.4 PHASE I: GEOGRAPHY DISTRIBUTION
26.6 MARKET BY APPLICATION
26.6.1 CANCER: GEOGRAPHY DISTRIBUTION
26.6.2 CARDIOVASCULAR DISEASES (CVDS): GEOGRAPHY DISTRIBUTION
26.6.3 NERVOUS SYSTEM DISORDERS: GEOGRAPHY DISTRIBUTION
26.6.4 INFECTIOUS DISEASES: GEOGRAPHY DISTRIBUTION
26.6.5 MUSCULOSKELETAL DISEASES: GEOGRAPHY DISTRIBUTION
26.6.6 GASTROENTEROLOGY DISEASES: GEOGRAPHY DISTRIBUTION
26.6.7 OTHER DISEASES: GEOGRAPHY DISTRIBUTION
26.7 MARKET BY END USER
26.7.1 SMALL & MID-SIZE COMPANIES: GEOGRAPHY DISTRIBUTION
26.7.2 LARGE ENTERPRISES: GEOGRAPHY DISTRIBUTION
27 APPENDIX
27.1 ABBREVIATIONS
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF GLOBAL CLINICAL TRIALS OUTSOURCING MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 TOTAL NUMBER OF CLINICAL TRIALS 2000–2020
EXHIBIT 4 CLINICAL TRIALS CONDUCTED BY COUNTRIES UNTIL 2022
EXHIBIT 5 GROWTH DRIVERS FOR CLINICAL TRIAL OUTSOURCING MARKET
EXHIBIT 6 CLINICAL TRIAL BY PHASE OF DEVELOPMENT 1999–2021
EXHIBIT 7 TOTAL NUMBER OF CLINICAL TRIALS BY PHASES 2022
EXHIBIT 8 CLINICAL TRIALS & PRE-FORMULATION CORRELATION
EXHIBIT 9 FACTORS DRIVING CLINICAL TRIAL OUTSOURCING
EXHIBIT 10 ESTIMATED NUMBER OF CLINICAL TRIALS REGISTERED 2000–2023
EXHIBIT 11 IMPACT OF RISING DEMAND FOR PATIENT-CENTRIC & DECENTRALIZED CLINICAL TRIALS
EXHIBIT 12 ADVANTAGES OF VIRTUAL CLINICAL TRIALS
EXHIBIT 13 IMPACT OF REVOLUTIONIZING EFFECTS OF AI ON CLINICAL TRIALS
EXHIBIT 14 BENEFITS OF AI IN CLINICAL TRIALS
EXHIBIT 15 IMPACT OF ENTRY OF START-UPS SPECIALIZING IN DRUG DISCOVERY
EXHIBIT 16 NEW DRUG APPROVALS BY DIFFERENT TYPES OF PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 2009–2018
EXHIBIT 17 IMPACT OF INCREASING ADOPTION OF SYNTHETIC CLINICAL TRIALS
EXHIBIT 18 IMPACT OF SURGE IN DRUG DISCOVERY INITIATIVES & ASSOCIATED EXPENDITURE
EXHIBIT 19 INCREASING EXPENDITURE & RISING DRUG DISCOVERY PROGRAMMES 2000–2021
EXHIBIT 20 NUMBER OF REGISTERED CLINICAL STUDIES 2000–2023
EXHIBIT 21 TOP PHARMACEUTICAL COMPANIES RANKED BY R&D SPENDING (% OF REVENUE)
EXHIBIT 22 DRUGS IN DEVELOPMENT BY THERAPEUTIC AREAS
EXHIBIT 23 IMPACT OF HIGH DEMAND FOR LARGE MOLECULE PRODUCTS & PERSONALIZED MEDICINES
EXHIBIT 24 CLASSIFICATION OF LARGE MOLECULES
EXHIBIT 25 NOVEL NEW DRUGS & BIOLOGICS DRUGS APPROVED BY FDA FOR RARE DISEASES UNTIL 2021
EXHIBIT 26 IMPACT OF INITIATIVES TO IMPROVE EFFICIENCY IN CLINICAL TRIALS
EXHIBIT 27 IMPACT OF RISE IN STRATEGIC PARTNERSHIPS AND R&D COLLABORATIONS
EXHIBIT 28 KEY THEMES FOR OPTIMIZING COLLABORATION EFFECTIVENESS
EXHIBIT 29 IMPACT OF GEOGRAPHICAL LOCATIONS & CRUCIAL REGULATORY ASPECTS FOR CLINICAL TRIALS
EXHIBIT 30 CHALLENGES IN CLINICAL RESEARCH AND CLINICAL TRIALS
EXHIBIT 31 IMPACT OF LONG TIMELINES AND LACK OF TRANSPARENCY & SPECIFICITY
EXHIBIT 32 IMPACT OF INCREASING COMPLEXITY OF CLINICAL TRIALS
EXHIBIT 33 FACTORS RESPONSIBLE FOR INCREASE IN COMPLEXITY OF CLINICAL TRIALS
EXHIBIT 34 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY: MARKET SHARE ANALYSIS 2021 & 2027
EXHIBIT 35 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE: MARKET SHARE ANALYSIS 2021 & 2027
EXHIBIT 36 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION: MARKET SHARE ANALYSIS 2021 & 2027
EXHIBIT 37 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END USER: MARKET SHARE ANALYSIS 2021 & 2027
EXHIBIT 38 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 39 FIVE FORCES ANALYSIS 2021
EXHIBIT 40 INCREMENTAL GROWTH BY PHASE 2021 & 2027
EXHIBIT 41 GLOBAL PHASE III CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 42 CLINICAL TRIAL OUTSOURCING MARKET BY PHASE 2022-2027
EXHIBIT 43 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE: OVERVIEW
EXHIBIT 44 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE: INCREMENTAL GROWTH
EXHIBIT 45 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE: ABSOLUTE GROWTH
EXHIBIT 46 PROBABILITY OF PHASE III SUCCESS 2010–2020
EXHIBIT 47 GLOBAL PHASE III CLINICAL TRIAL OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL PHASE II CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 49 GLOBAL PHASE II CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 50 GLOBAL PHASE IV CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 51 PHASE IV: STUDIES CONDUCTED IN PHASE IV
EXHIBIT 52 GLOBAL PHASE IV CLINICAL TRIAL OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 53 GLOBAL PHASE I CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 54 GLOBAL PHASE I CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 55 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 56 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2022–2027
EXHIBIT 57 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION: OVERVIEW
EXHIBIT 58 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION: INCREMENTAL GROWTH
EXHIBIT 59 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION: ABSOLUTE GROWTH
EXHIBIT 60 ONCOLOGY CLINICAL TRIALS BY PHASE 2020 (%).
EXHIBIT 61 PERCENTAGE OF DRUG PIPELINES DEDICATED TO CANCER 2010–2019
EXHIBIT 62 GLOBAL CANCER CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 63 GLOBAL CANCER CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 64 CARDIOVASCULAR DISEASES: GROUP OF DISEASES OF BLOOD VESSELS AND HEART
EXHIBIT 65 GLOBAL CARDIOVASCULAR DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 66 GLOBAL CARDIOVASCULAR DISEASES CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 67 GLOBAL PREVALENCE OF NEUROLOGICAL DISORDERS 2019–2021
EXHIBIT 68 GLOBAL NERVOUS SYSTEM DISORDERS CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 69 GLOBAL NERVOUS SYSTEM DISORDERS CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 70 PATIENT POPULATION FOR INFECTIOUS DISEASES
EXHIBIT 71 GLOBAL INFECTIOUS DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 72 GLOBAL INFECTIOUS DISEASES CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 73 PREVALENCE OF MUSCULOSKELETAL CONDITIONS WORLDWIDE 2021
EXHIBIT 74 PREVALENCE OF MUSCULOSKELETAL DISEASES BY CONDITION 2021
EXHIBIT 75 GLOBAL MUSCULOSKELETAL DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 76 GLOBAL MUSCULOSKELETAL DISEASES CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 77 GLOBAL GASTROENTEROLOGY DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 78 GLOBAL GASTROENTEROLOGY DISEASES CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 79 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY OTHER DISEASES: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 80 GLOBAL OTHER DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 81 INCREMENTAL GROWTH BY END USER 2021 & 2027
EXHIBIT 82 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2022–2027
EXHIBIT 83 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END-USER: OVERVIEW
EXHIBIT 84 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END-USER: GROWTH POTENTIAL
EXHIBIT 85 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END USER: INCREMENTAL GROWTH
EXHIBIT 86 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END USER: ABSOLUTE GROWTH
EXHIBIT 87 NUMBER OF SMALL PHARMACEUTICAL/ BIOTECHNOLOGY COMPANIES WITH ACTIVE PIPELINES 2010–2019
EXHIBIT 88 DRIVERS FOR CLINICAL TRIAL OUTSOURCING BY SMALL- & MID-SIZE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
EXHIBIT 89 SMALL PHARMACEUTICAL/BIOTECHNOLOGY COMPANIES CONTRIBUTION TO NEW DRUG APPROVAL BY FDA 2020
EXHIBIT 90 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID SIZE ENTERPRISES 2021–2027 ($ BILLION)
EXHIBIT 91 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID SIZE ENTERPRISES: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 92 TOP PHARMA COMPANIES WITH HIGH R&D EXPENDITURE 2021 (CHANGE FROM 2020-%) BILLION
EXHIBIT 93 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 94 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES 2021–2027 ($ BILLION)
EXHIBIT 95 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 96 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2022-2027
EXHIBIT 97 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 98 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 99 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET 2000–2021
EXHIBIT 100 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET: KEY COUNTRIES
EXHIBIT 101 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 102 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 103 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 104 PERCENTAGE OF REGISTERED CLINICAL STUDIES BY LOCATION APRIL 2022 (TOTAL 410,703)
EXHIBIT 105 CLINICAL TRIALS IN DIFFERENT THERAPEUTIC AREAS ACROSS US 2019
EXHIBIT 106 US CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 107 CANADA: WORLD LEADING DESTINATION FOR CLINICAL TRIALS
EXHIBIT 108 CANADA CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 109 EUROPE CLINICAL TRIALS OUTSOURCING MARKET: KEY COUNTRIES
EXHIBIT 110 EUROPE CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 111 EUROPE CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 112 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 113 INDUSTRY-SPONSORED CLINICAL TRIALS IN GERMANY 2011–2020 (%)
EXHIBIT 114 INDUSTRY-SPONSORED CLINICAL TRIALS FOR DIFFERENT THERAPEUTIC AREAS IN GERMANY 2020 (%)
EXHIBIT 115 GERMANY CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 116 CLINICAL TRIALS FUNDING & SOURCES IN UK
EXHIBIT 117 UK CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 118 TOP THERAPY AREAS OF INDUSTRY-SPONSORED CLINICAL TRIALS IN FRANCE 2020 (%)
EXHIBIT 119 FRANCE CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 120 SPAIN CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 121 TOP THERAPY AREAS FOR INDUSTRY-SPONSORED CLINICAL TRIALS IN ITALY
EXHIBIT 122 ITALY CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 123 APAC CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 124 REASONS FOR APAC BEING PREFERRED DESTINATION FOR CLINICAL TRIALS OUTSOURCING
EXHIBIT 125 APAC CLINICAL TRIAL OUTSOURCING MARKET: KEY COUNTRIES
EXHIBIT 126 APAC CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 127 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 128 CHINA: FACTORS INFLUENCING CLINICAL TRIAL OUTSOURCING MARKET GROWTH
EXHIBIT 129 CHINA: CLINICAL TRIALS 2012–2021 (TEN YEAR TREND)
EXHIBIT 130 CHINA CLINICAL TRIAL OUTSOURCING DRIVERS
EXHIBIT 131 CHINA CLINICAL TRIAL OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 132 JAPAN CLINICAL TRIAL OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 133 FACTORS TRIGGERING CLINICAL TRIAL OUTSOURCING IN INDIA
EXHIBIT 134 INDIA: CLINICAL TRIALS TEN YEAR TREND 2011–2020 (%)
EXHIBIT 135 INDIA CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 136 AUSTRALIA CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 137 SOUTH KOREA: FACTOR INFLUENCING OUTSOURCING CLINICAL TRIALS DEMAND
EXHIBIT 138 SOUTH KOREA CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 139 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET: KEY COUNTRIES
EXHIBIT 140 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 141 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 142 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 143 BRAZIL CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 144 MEXICO CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 145 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET: KEY COUNTRIES
EXHIBIT 146 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 147 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
EXHIBIT 148 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 149 DRIVERS FOR TURKEY CLINICAL TRIAL OUTSOURCING MARKET
EXHIBIT 150 TURKEY CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 151 NUMBER OF CLINICAL TRIALS IN EGYPT 2008–2017
EXHIBIT 152 EGYPT CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 153 NUMBER OF CLINICAL TRIALS IN EGYPT PER YEAR
EXHIBIT 154 SOUTH AFRICA CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 155 SAUDI ARABIA CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 156 PURE & DIVERSIFIED VENDORS IN GLOBAL CLINICAL TRIALS OUTSOURCING MARKET
EXHIBIT 157 VENDORS OFFERING CLINICAL TRIALS OUTSOURCING: MARKET DOMINANCE ANALYSIS
EXHIBIT 158 VENDORS OFFERING CLINICAL TRIALS OUTSOURCING: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 159 CHARLES RIVER LABORATORIES: REVENUE BY BUSINESS SEGMENT 2021
EXHIBIT 160 CHARLES RIVER LABORATORIES: REVENUE BY CLIENT SEGMENT 2021
EXHIBIT 161 CHARLES RIVER LABORATORIES: REVENUE BY GEOGRAPHY
EXHIBIT 162 CHARLES RIVER LABORATORIES: ANNUAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 163 IQVIA: REVENUE 2019–2021 ($ MILLION).
EXHIBIT 164 IQVIA: R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 165 ICON PLC: ANNUAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 166 LABCORP DRUG DEVELOPMENT: REVENUE 2019–2021 (MILLION)
EXHIBIT 167 SYNEOS HEALTH: REVENUE 2019–2021 ($ BILLION)
EXHIBIT 168 THERMO FISHER SCIENTIFIC: REVENUE 2019–2021 ($ MILLION)
EXHIBIT 169 THERMO FISHER SCIENTIFIC: REVENUE BY LABORATORY PRODUCTS & BIOPHARMA SERVICES SEGMENT 2019– 2021 ($ MILLION)
EXHIBIT 170 THERMO FISHER SCIENTIFIC: TOTAL REVENUE BY GEOGRAPHIES 2019–2021 ($ MILLION)
EXHIBIT 171 WUXI APPTEC: REVENUE 2019–2021 ($ BILLION)
EXHIBIT 172 WUXI APPTEC: REVENUE BY GEOGRAPHY (%) 2021
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015–2021
TABLE 3 GLOBAL PHASE III CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)
TABLE 4 GLOBAL PHASE III CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 (%) (GEOGRAPHY)
TABLE 5 GLOBAL PHASE II CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)
TABLE 6 GLOBAL PHASE II CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 (%) (GEOGRAPHY)
TABLE 7 GLOBAL PHASE IV CLINICAL TRIAL OUTSOURCING MARKET BY GEOGRAPHY 2021–2027 ($ BILLION)
TABLE 8 GLOBAL PHASE IV CLINICAL TRIAL OUTSOURCING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 9 GLOBAL PHASE I CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021–2027 ($ BILLION)
TABLE 10 GLOBAL PHASE I CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 11 GLOBAL CANCER CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021–2027 ($ BILLION)
TABLE 12 GLOBAL CANCER CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 13 GLOBAL CARDIOVASCULAR DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)
TABLE 14 GLOBAL CARDIOVASCULAR DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 (%) (GEOGRAPHY)
TABLE 15 GLOBAL NERVOUS SYSTEM DISORDERS CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)
TABLE 16 GLOBAL NERVOUS SYSTEM DISORDERS CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 (%) (GEOGRAPHY)
TABLE 17 GLOBAL INFECTIOUS DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)
TABLE 18 GLOBAL INFECTIOUS DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 (%) (GEOGRAPHY)
TABLE 19 GLOBAL MUSCULOSKELETAL DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)
TABLE 20 GLOBAL MUSCULOSKELETAL DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 (%) (GEOGRAPHY)
TABLE 21 GLOBAL GASTROENTEROLOGY DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION)
TABLE 22 GLOBAL GASTROENTEROLOGY DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 (%)
TABLE 23 GLOBAL OTHER DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)
TABLE 24 GLOBAL OTHER DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021–2027 (%) (GEOGRAPHY)
TABLE 25 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID SIZE ENTERPRISES 2021–2027 ($ BILLION)
TABLE 26 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID SIZE ENTERPRISES 2021–2027 (%)
TABLE 27 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES 2021–2027 ($ BILLION) (GEOGRAPHY)
TABLE 28 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES 2021–2027 (%) (GEOGRAPHY)
TABLE 29 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 ($ BILLION)
TABLE 30 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 (%)
TABLE 31 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 32 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 (%)
TABLE 33 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 34 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 (%)
TABLE 35 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 ($ BILLION)
TABLE 36 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 (%)
TABLE 37 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 38 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 (%)
TABLE 39 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 40 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 (%)
TABLE 41 APAC CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 ($ BILLION)
TABLE 42 APAC CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 (%)
TABLE 43 APAC CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 44 APAC CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 (%)
TABLE 45 APAC CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 46 APAC CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 (%)
TABLE 47 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 ($ BILLION)
TABLE 48 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 (%)
TABLE 49 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 50 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 (%)
TABLE 51 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 52 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 (%)
TABLE 53 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 ($ BILLION)
TABLE 54 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 (%)
TABLE 55 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 56 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 (%)
TABLE 57 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 58 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 (%)
TABLE 59 CHARLES RIVER LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 60 IQVIA: MAJOR PRODUCT OFFERINGS
TABLE 61 ICON PLC: MAJOR PRODUCT OFFERINGS
TABLE 62 LABCORP DRUG DEVELOPMENT: MAJOR SERVICE OFFERINGS
TABLE 63 SYNEOS HEALTH: MAJOR SERVICE OFFERINGS
TABLE 64 THERMO FISHER SCIENTIFIC: MAJOR SERVICE OFFERINGS
TABLE 65 WUXI APPTEC: MAJOR SERVICE OFFERINGS
TABLE 66 PARAXEL: MAJOR SERVICE OFFERINGS
TABLE 67 ADVANCED CLINICAL: MAJOR SERVICE OFFERINGS
TABLE 68 BIOANALYTIX: MAJOR SERVICE OFFERINGS
TABLE 69 CURIA GLOBAL: MAJOR SERVICE OFFERINGS
TABLE 70 CMED: MAJOR SERVICE OFFERINGS
TABLE 71 CROMOS PHARMA: MAJOR SERVICE OFFERINGS
TABLE 72 CRITERIUM: MAJOR SERVICE OFFERINGS
TABLE 73 KCR S.A.: MAJOR SERVICE OFFERINGS
TABLE 74 MEDPACE: MAJOR SERVICE OFFERINGS
TABLE 75 MEDELIS: MAJOR SERVICE OFFERINGS
TABLE 76 OCT GROUP: MAJOR SERVICE OFFERINGS
TABLE 77 PROTRIALS RESEARCH: MAJOR SERVICE OFFERINGS
TABLE 78 PROMETRIKA: MAJOR SERVICE OFFERINGS
TABLE 79 QUALITY DATA SERVICES: MAJOR SERVICE OFFERINGS
TABLE 80 QPS: MAJOR SERVICE OFFERINGS
TABLE 81 SOFPROMED: MAJOR SERVICE OFFERINGS
TABLE 82 VERISTAT: MAJOR SERVICE OFFERINGS
TABLE 83 WORLDWIDE CLINICAL TRIALS: MAJOR SERVICE OFFERINGS
TABLE 84 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021–2027 ($ BILLION)
TABLE 85 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 86 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 ($ BILLION)
TABLE 87 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021–2027 (%)
TABLE 88 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 89 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021–2027 (%)
TABLE 90 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 91 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021–2027 (%)
TABLE 92 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE III 2021–2027 ($ BILLION) (GEOGRAPHY)
TABLE 93 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE III 2021–2027 (%) (GEOGRAPHY)
TABLE 94 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE II 2021–2027 (%) (GEOGRAPHY)
TABLE 95 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE II 2021–2027 (%) (GEOGRAPHY)
TABLE 96 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE IV 2021–2027 (%) (GEOGRAPHY)
TABLE 97 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE IV 2021–2027 (%) (GEOGRAPHY)
TABLE 98 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE I 2021–2027 (%) (GEOGRAPHY)
TABLE 99 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE I 2021–2027 (%) (GEOGRAPHY)
TABLE 100 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY CANCER 2021–2027 (%) (GEOGRAPHY)
TABLE 101 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY CANCER 2021–2027 (%) (GEOGRAPHY)
TABLE 102 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY CARDIOVASCULAR DISEASES 2021–2027 (%) (GEOGRAPHY)
TABLE 103 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY CARDIOVASCULAR DISEASES 2021–2027 (%) (GEOGRAPHY)
TABLE 104 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY NERVOUS SYSTEM DISORDERS 2021–2027 (%) (GEOGRAPHY)
TABLE 105 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY NERVOUS SYSTEM DISORDERS 2021–2027 (%) (GEOGRAPHY)
TABLE 106 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY INFECTIOUS DISEASES 2021–2027 (%) (GEOGRAPHY)
TABLE 107 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY INFECTIOUS DISEASES 2021–2027 (%) (GEOGRAPHY)
TABLE 108 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY MUSCULOSKELETAL DISEASES 2021–2027 (%) (GEOGRAPHY)
TABLE 109 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY MUSCULOSKELETAL DISEASES 2021–2027 (%) (GEOGRAPHY)
TABLE 110 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GASTROENTEROLOGY DISEASES 2021–2027 (%) (GEOGRAPHY)
TABLE 111 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GASTROENTEROLOGY DISEASES 2021–2027 (%) (GEOGRAPHY)
TABLE 112 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY OTHER DISEASES 2021–2027 (%) (GEOGRAPHY)
TABLE 113 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY OTHER DISEASES 2021–2027 (%) (GEOGRAPHY)
TABLE 114 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID-SIZE ENTERPRISES 2021–2027 (%) (GEOGRAPHY)
TABLE 115 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID-SIZE ENTERPRISES 2021–2027 (%) (GEOGRAPHY)
TABLE 116 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES 2021–2027 (%) (GEOGRAPHY)
TABLE 117 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES 2021–2027 (%) (GEOGRAPHY)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
